Skip to main content
Clinical Trials/JPRN-jRCTs051190072
JPRN-jRCTs051190072
Completed
未知

Prospective study regarding the improving effect of Go-sha-jinki-gan on frailty(Single-group, open-label study)

Hagihara Keisuke0 sites20 target enrollmentNovember 7, 2019

Overview

Phase
未知
Intervention
Not specified
Conditions
Frailty or prefrailty.
Sponsor
Hagihara Keisuke
Enrollment
20
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 7, 2019
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Hagihara Keisuke

Eligibility Criteria

Inclusion Criteria

  • 1\) Patients who meet a criterion for frailty or pre\-frailty by J\-CHS.
  • 2\) Patients with low muscle strength(hand grip strength: less than 26 kg for men and 18 kg for women) or low physical performance (below normal gait speed 1m/s)
  • 3\) Patients who are 65 years old or older at the time of informed consent and do not received certification of needed support or needed long\-term care.
  • 4\) Patients who can go to hospital for outpatient.
  • 5\) Patients who can take Kampo medicine preparations orally.
  • 6\) Patients who obtained written consent for this study.

Exclusion Criteria

  • 1\)Patients who took Kampo medicine preparation within 4 weeks from the start of treatment.
  • 2\)Patients who have allergic episode with Kampo medicine preparations in the past.
  • 3\)Patients with obvious joint deformities due to rheumatoid arthritis etc.
  • 4\)Patients who has serious complicated disease (disease such as liver, kidney, heart, lung, blood, metabolic, or malignant tumor).
  • 5\)Patients who have embedded medical devices such as cardiac pacemakers.
  • 6\)Patients suspected of having dementia (MMSE score 23 or below).
  • 7\)Patients who are participating in or are planning to participate in clinical trials or other clinical studies.
  • 8\)Patients who are considered ineligible to participate by principal investigator or sub\-investigator.

Outcomes

Primary Outcomes

Not specified

Similar Trials